David C. Helfgott, MD

David C. Helfgott, MD, received his BA at the University of Pennsylvania and his MD at the Yale University School of Medicine. Dr Helfgott did his internship and residency at The New York Hospital and his infectious diseases fellowship at Cornell University Medical College. He is assistant attending physician at The New York-Presbyterian Hospital and assistant clinical professor of medicine at Weill Cornell Medical College. He works closely with the leukemia service there and has been involved in clinical studies of patients with infectious complications of acute leukemia.

All articles by David C. Helfgott, MD

Pleuropulmonary and Bronchial Infections

Pediatric Vaccinations Are Being Missed During the SARS-CoV-2 Pandemic

The decline in vaccination rates during the SARS-CoV-2 pandemic could lead to global outbreaks of communicable infectious diseases.

David C. Helfgott, MD

June 18, 2020

Pleuropulmonary and Bronchial Infections

Remdesivir: Does It Have a Place in the Treatment of COVID-19?

The US Food and Drug Administration has issued an emergency use authorization for the use of remdesivir in the treatment of COVID-19 infection in patients with oxygen saturation on room air ≤94% requiring supplemental oxygen, mechanical ventilation, or extracorporeal membrane oxygenation.

David C. Helfgott, MD

May 19, 2020

Pleuropulmonary and Bronchial Infections

The Seasonality Issue: Wishful Thinking for SARS-CoV-2?

It is certainly too early to know if there will be any seasonal variation to SARS-CoV-2 infection, and there is no reason to specifically compare this virus with the seasonal behavior of influenza virus or to other seasonal respiratory viruses.

David C. Helfgott, MD

May 7, 2020

Pleuropulmonary and Bronchial Infections

Respiratory Transmission of SARS-CoV-2: What Do We Really Know?

Although influenza virus and respiratory syncytial virus are considered to be spread by droplets and aerosol transmission, the mode of respiratory transmission of SARS-CoV-2 is not completely understood.

David C. Helfgott, MD

April 22, 2020

Pleuropulmonary and Bronchial Infections

Hydroxychloroquine for SARS-CoV-2 Infection: How Did We Get Here?

Hydroxychloroquine is a less-toxic metabolite of the antimalarial drug chloroquine and is used as an immunomodulator for the treatment of autoimmune diseases.

David C. Helfgott, MD

April 8, 2020

General Infectious Disease

Infections Complicating the Use of Monoclonal Antibodies for Malignancy

In this review, David C. Helfgott, MD, editorial advisory board member for Infectious Disease Advisor, focuses on infectious complications from the use of monoclonal antibodies for malignancy.

David C. Helfgott, MD

May 7, 2018

Central Nervous System Infections

Infections Complicate Biologic Use in Autoimmune Inflammatory Disorders

The risk for infection and malignancy associated with biologic use complicates the management of patients with a deficient immune system. Equip yourself with the information needed to effectively manage these complex patients.

David C. Helfgott, MD

July 14, 2017